Cargando…

Oligometastasis and oligo-recurrence: more than a mirage

The standard treatment choice for cancer metastasis has been systemic management, including cytotoxic chemotherapy, hormonal manipulation, and targeted therapy. Emerging evidence has shown an oligometastatic state, an intermediate state between limited primary cancer and polymetastatic cancer, in wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Fang, Wu, Gang, Yang, Kunyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222373/
https://www.ncbi.nlm.nih.gov/pubmed/25359216
http://dx.doi.org/10.1186/s13014-014-0230-6
_version_ 1782343025671798784
author Huang, Fang
Wu, Gang
Yang, Kunyu
author_facet Huang, Fang
Wu, Gang
Yang, Kunyu
author_sort Huang, Fang
collection PubMed
description The standard treatment choice for cancer metastasis has been systemic management, including cytotoxic chemotherapy, hormonal manipulation, and targeted therapy. Emerging evidence has shown an oligometastatic state, an intermediate state between limited primary cancer and polymetastatic cancer, in which local therapy for metastatic lesions results in satisfactory survival comparable to non-metastatic disease. We provide a comprehensive introduction of evidence from experimental and clinical studies in favor of the oligometastatic phenotype, we review the efficacy and safety of surgery and stereotactic body radiotherapy in the treatment of oligometastases, and finally, we discuss the way to differentiate the oligometastatic state from polymetastasis.
format Online
Article
Text
id pubmed-4222373
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42223732014-11-07 Oligometastasis and oligo-recurrence: more than a mirage Huang, Fang Wu, Gang Yang, Kunyu Radiat Oncol Review The standard treatment choice for cancer metastasis has been systemic management, including cytotoxic chemotherapy, hormonal manipulation, and targeted therapy. Emerging evidence has shown an oligometastatic state, an intermediate state between limited primary cancer and polymetastatic cancer, in which local therapy for metastatic lesions results in satisfactory survival comparable to non-metastatic disease. We provide a comprehensive introduction of evidence from experimental and clinical studies in favor of the oligometastatic phenotype, we review the efficacy and safety of surgery and stereotactic body radiotherapy in the treatment of oligometastases, and finally, we discuss the way to differentiate the oligometastatic state from polymetastasis. BioMed Central 2014-10-31 /pmc/articles/PMC4222373/ /pubmed/25359216 http://dx.doi.org/10.1186/s13014-014-0230-6 Text en © Huang et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Huang, Fang
Wu, Gang
Yang, Kunyu
Oligometastasis and oligo-recurrence: more than a mirage
title Oligometastasis and oligo-recurrence: more than a mirage
title_full Oligometastasis and oligo-recurrence: more than a mirage
title_fullStr Oligometastasis and oligo-recurrence: more than a mirage
title_full_unstemmed Oligometastasis and oligo-recurrence: more than a mirage
title_short Oligometastasis and oligo-recurrence: more than a mirage
title_sort oligometastasis and oligo-recurrence: more than a mirage
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222373/
https://www.ncbi.nlm.nih.gov/pubmed/25359216
http://dx.doi.org/10.1186/s13014-014-0230-6
work_keys_str_mv AT huangfang oligometastasisandoligorecurrencemorethanamirage
AT wugang oligometastasisandoligorecurrencemorethanamirage
AT yangkunyu oligometastasisandoligorecurrencemorethanamirage